Publications by authors named "C Dalban"
Background: Nivolumab is an immune checkpoint inhibitor (ICI) that selectively inhibits programmed cell death protein 1 activation, restoring antitumor immunity. ICIs are indicated for various types of advanced solid tumors; however, not all patients benefit from them, and tools that could be used in the clinic to predict response to treatment represent an unmet need. Here we describe the development of a new population pharmacokinetic (PPK) model in patients treated with nivolumab in clinical trials.
View Article and Find Full Text PDFArticle Synopsis
- The study examines the Lung Immune Prognostic Index (LIPI) to see if it can predict survival in patients with metastatic renal cell carcinoma (mRCC).
- LIPI categorizes patients into groups based on specific blood markers, and results show that those with a better LIPI score have significantly longer overall and progression-free survival.
- The findings indicate that LIPI can be a useful prognostic tool for mRCC patients regardless of the type of treatment they receive, whether it’s immune checkpoint inhibitors or antiangiogenic therapy.
Introduction: Immune checkpoint inhibitors are standard of care in metastatic renal cell carcinoma but their activity and safety in elderly patients is insufficiently explored. We evaluated outcomes of elderly patients with mRCC treated with nivolumab in the GETUG-AFU 26 NIVOREN phase 2 trial (NCT03013335) and conducted exploratory circulating biomarker analyses.
Methods: Patients with mRCC were treated with nivolumab after at least one antiangiogenic therapy.
Article Synopsis
- Glandular metastases (GMs) are uncommon in metastatic clear cell renal cell carcinoma (mccRCC), but patients with GMs treated with antiangiogenic therapy show better survival outcomes.
- The GETUG-AFU-26 NIVOREN trial analyzed the effects of nivolumab on mccRCC patients, categorizing them based on the presence of GMs to compare survival outcomes.
- Among 720 patients, those with adrenal GMs had poorer overall survival and response rates, while those with pancreatic GMs had significantly better survival rates compared to nonpancreatic metastasis.
Background: In metastatic renal clear cell carcinoma (ccRCC), vascular endothelial growth factor receptor (VEGFR) and immune checkpoint are 2 main therapeutic targets. We investigated the impact of duration exposure to antiangiogenic on immunotherapy clinical outcomes in metastatic ccRCC.
Methods: Patients from NIVOREN trial who received nivolumab after only 1 prior antiangiogenic therapy were included.